CompletedPhase 4

Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream

Finland10 participantsStarted 2016-02

Plain-language summary

This study investigates the efficacy of photodynamic therapy (PDT) in the treatment of lentigo maligna (LM). Hyperspectral imaging system (HIS) will be used to determine the margins of LM and to rule out possible invasion. Participants will receive photodynamic therapy three times consecutively with intervals of two weeks using 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream. Four weeks after last photodynamic therapy the lentigo maligna lesion will be excised surgically from the skin. Result of the treatment is assessed with histopathological examination and immunohistochemical staining of removed tissue specimen.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with non-invasive lentigo maligna located in the skin of face, neck or upper body region Exclusion Criteria: * Biopsy shows invasive melanoma inside lentigo maligna lesion prior treatment * Porphyria or solar dermatitis * Allergy for photosensitizer (5-aminolaevulinic acid) used in study * Pregnant or breastfeeding patients

What they're measuring

The histopathological and immunohistochemical curing of lentigo maligna

Timeframe: 2 months

Trial details

NCT IDNCT02685592

SponsorJoint Authority for Päijät-Häme Social and Health Care

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-03

View on ClinicalTrials.gov More Lentigo Maligna trials